NICE verdict on Temozolomide: where next? by Brada, M
Editorial
NICE verdict on Temozolomide: where next?
M Brada*
,1
1The Institute of Cancer Research and The Royal Marsden NHS Trust, Downs Road, Sutton, Surrey SM2 5PT, UK
British Journal of Cancer (2002) 86, 499–500. DOI: 10.1038/sj/bjc/6600134 www.bjcancer.com
ã 2002 Cancer Research UK
Temozolomide is a UK product developed in a CRC laboratory at
Aston University by Malcolm Stevens and his team. It came to
clinical testing in the early 1990s and the ﬁrst UK study suggested
activity in recurrent malignant glioma beyond that perceived for
conventional therapy (O’Reilly et al, 1993). This raised hope in a
largely chemoresistant tumour with poor prognosis. However, the
subsequent UK experience in a CRC multicentre phase II study
in recurrent malignant glioma did not reproduce the results
expected from the initial experience (Bower et al, 1997). Time
moved on and Temozolomide was licenced to Schering Plough.
Following three preregistration studies which were the largest ever
performed in patients with recurrent malignant glioma (Yung et al,
1999, 2000; Brada et al, 2001) it became available in clinical prac-
tice. The median progression free survival and survival were 5.4
and 13.6 months in anaplastic astrocytoma and 3 and 7.3 months
in glioblastoma with 35% response rate in anaplastic astrocytoma
and 6–8% in glioblastoma multiforme and quality of life beneﬁt.
Two studies had no comparative group and one randomized Phase
II study demonstrated small progression free survival gain
compared to single agent Procarbazine with no survival beneﬁt
(Yung et al, 2000).
The introduction of a new chemotherapeutic agent in EU coun-
tries is through product authorization by the European Agency for
the Evaluation of Medicinal Products (EMEA) which allows for
sales for a speciﬁed indication. This however does not lead to free
availability within the National Health Service. Currently the
release of funding for new treatment is strongly inﬂuenced by a
NICE (National Institute of Clinical Excellence) review.
It is reasonable to ask whether the NICE process is necessary
following a full review by EMEA prior to drug registration. The
answer is complex and highlights the different requirements and
responsibilities of each of the organisations. It also reﬂects the
different approaches to the introduction of new therapies in the
UK and other EU member states.
Be that as it may, we are presented with a review commissioned
by the Health Technology Assessment (HTA) programme on behalf
of NICE and the summary is reported in this issue of the journal
(Dinnes et al, this issue). From the publication it is clear that the
structured evaluation of Temozolomide studies looked at issues of
efﬁcacy and toxicity in a different manner than EMEA. An author-
ity granting a product licence asks whether an agent works and
whether it is safe. The requirement is for ‘signiﬁcant therapeutic
innovation’ although the term is not fully deﬁned. The remit of
NICE evaluation is to provide guidance on clinical and cost effec-
tiveness of new treatment. The attempt is to stay clear of political
and commercial pressures and come up with as objective an assess-
ment as is possible with vested interests hovering in the wings.
The systematic Cochrane type review of published articles
(described in detail in the full publication (Dinnes et al, 2001)
concludes that the evidence base for the use of Temozolomide in
malignant glioma is ‘weak and few strong conclusions can be
drawn regarding its effectiveness’ (Dinnes et al, this issue). This
is in stark contrast to the description of the agent during its launch
as ‘the most important advance in brain cancer treatment for the
past 20 years’.
There is little disagreement that the last 20 years have not been a
very productive period for the development of new treatments in
malignant gliomas and it may well be that a new drug with
promise is an addition which is sorely needed.
Temozolomide is an interesting agent with little toxicity and
easy method of administration, but of limited efﬁcacy in recurrent
malignant gliomas, particularly glioblastoma multiforme. This is
not surprising in the face of a tumour which has frustrated most
therapeutic endeavours. In retrospect it is too much to expect
for a new single agent, whose primary mode of action is a common
alkylating path, to be highly effective in a largely chemoresistant
tumour. Nevertheless selected patients with recurrent anaplastic
astrocytoma with good performance status have an objective
response rate higher than previously perceived for malignant glio-
ma (Yung et al, 1999) although comparative information on such a
selected cohort is not available.
While commercial interest is understandably directed to explor-
ing the use of Temozolomide in common tumours we must not
lose sight of the opportunity to deﬁne its role in the management
of glial tumours. An important step missing from initial glioma
studies is a head to head comparison with conventional treatment
particularly at the time of recurrence. To this end a randomized
CRC/NCRI study comparing Temozolomide and nitrosoureas is
due to commence in early 2002. The EORTC brain tumour group
and RTOG have also commenced randomized studies of single
agent Temozolomide in primary malignant glioma concomitant
with and adjuvant to radiotherapy.
There is also a need to determine the optimum scheduling of
Temozolomide. A number of alternative schedules of administra-
tion have been investigated aiming for higher dose intensity and
saturating DNA repair enzyme through prolonged and/or multiple
day administration (Brock et al, 1998; Middleton et al, 2000; Spiro
et al, 2001) but higher efﬁcacy in clinical setting has not yet been
demonstrated. Temozolomide is also under test in combination
with a variety of other agents but the present design of phase II Received 7 December 2001; accepted 14 December 2001
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winner (Gander et al, 1999; Britten et al, 1999; Patel et al, 2000).
The potentially most promising avenue for increasing the efﬁcacy
of Temozolomide is through modulation of drug resistance. The
two main resistance mechanisms for Temozolomide induced
DNA damage are via demethylation through O
6-alkylguanine
DNA alkyltransferase (AGT) and repair by DNA mismatch repair
protein (Baer et al, 1993; Liu et al, 1996; Wedge and Newlands,
1996). In vitro and in vivo depletion of AGT increases Temozolo-
mide cytotoxicity (Wedge et al, 1997; Middleton et al, 1998,
2000). However published clinical studies showing convincing
improvement in therapeutic ratio are not yet available.
The availability of Temozolomide has generated new research
activity in a relatively unexplored tumour. Activity does not neces-
sarily equate with progress and to accomplish real improvement we
need to take a lesson from the past. Clinical trials conducted over
the last 20 years aiming to evaluate new agents in the management
of patients with malignant glioma have largely failed to ﬁnd new
effective treatment strategies. While this may be due to primary
resistance of malignant glioma to therapy, it may also in part be
due to inadequate trial design and inappropriate or difﬁcult
endpoints (Brada et al, 1999).
To some the assessment of Temozolomide may seem unduly
harsh. Nevertheless it provides a clear message that the new agent
is not a panacea. We should therefore avoid the trap of wide-
spread use and concentrate on studies to optimize the potential
of what is an interesting new oral chemotherapeutic agent. To
grasp the opportunity to develop more effective therapy in malig-
nant glioma incorporating Temozolomide will require robust and
reliable study design coupled with intellectually honest interpreta-
tion of results. Quick ﬁx is unlikely to avoid the failure of the last
20 years.
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